Diabetes mellitus. Considerations for dentistry

Journal of the American Dental Association

Volumn 139, Issue 10 SUPPL., 2008, Pages 8S-18S

  Kidambi, Srividya ^a   Patel, Shailendra B ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diabetes; Hypoglycemia; Insulin; Periodontal disease

Indexed keywords

EID: 54449097391     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics, 2007. "http//diabetes.niddk.nih.gov/dm/pubs/ statistics". Accessed July 28, 2008.
2. McGarry JD. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 1992;258(5083):766-770.
3. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51(1):7-18.
4. Ryan ME, Carnu O, Kamer A. The influence of diabetes on the periodontal tissues. JADA 2003;134(spec no.):34S-40S.
5. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007;22(9):1317-1328.
6. Sidiropoulou-Chatzigiannis S, Kourtidou M, Tsalikis L. The effect of osteoporosis on periodontal status, alveolar bone and orthodontic tooth movement: a literature review. J Int Acad Periodontol 2007;9(3):77-84.
7. Ford PJ, Gemmell E, Timms P, Chan A, Preston FM, Seymour GJ. Anti-P. gingivalis response correlates with atherosclerosis. J Dent Res 2007;86(1):35-40.
8. Ford PJ, Yamazaki K, Seymour GJ. Cardiovascular and oral disease interactions: what is the evidence? Prim Dent Care 2007;14(2):59-66.
9. Seymour GJ, Ford PJ, Cullinan MP, Leishman S, Yamazaki K. Relationship between periodontal infections and systemic disease. Clin Microbiol Infect 2007;13(suppl 4):3-10.
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31(suppl 1):S55-S60.
11. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group (published correction appears in Lancet 1999;354[9178]:602). Lancet 1998;352(9131):837-853.
12. Duffy DL. Genetic determinants of diabetes are similarly associated with other immune-mediated diseases. Curr Opin Allergy Clin Immunol 2007;7(6):468-474.
13. Haller MJ, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology, presentation, and management. Pediatr Clin North Am 2005;52(6):1553-1578.
14. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008;31(suppl 2):S262-S268.
15. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001;86(8): 3574-3578.
16. Gavin JR 3rd, Roth J, Neville DM Jr, de Meyts P, Buell DN. Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. Proc Natl Acad Sci U S A 1974;71(1):84-88.
17. Le Marchand Y, Loten EG, Assimacopoulos-Jeannet F, Forgue ME, Freychet P, Jeanrenaud B. Effect of fasting and streptozotocin in the obese-hyperglycemic (ob/ob) mouse: apparent lack of a direct relationship between insulin binding and insulin effects. Diabetes 1977;26(6):582-590.
18. Zick Y. Role of Ser/Thr kinases in the uncoupling of insulin signaling. Int J Obes Relat Metab Disord 2003;27(suppl 3):S56-S60.
19. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 2007;8(9):657-662.
20. Dabelea D. The predisposition to obesity and diabetes in offspring of diabetic mothers (published correction appears in Diabetes Care 2007;30[12]:3154). Diabetes Care 2007;30(suppl 2):S169-S174.
21. Buchanan TA, Xiang A, Kjos SL, Watanabe R. What is gestational diabetes (published correction appears in Diabetes Care 2007;30[12]:3154)? Diabetes Care 2007;30(suppl 2):S105-S111.
22. O'Sullivan JB. Diabetes mellitus after GDM. Diabetes 1991;40(suppl 2):131-135.
23. Ratner RE. Prevention of type 2 diabetes in women with previous gestational diabetes (published correction appears in Diabetes Care 2007;30[12]:3154). Diabetes Care 2007;30(suppl 2):S242-S245.
24. Metzger BE. Long-term outcomes in mothers diagnosed with gestational diabetes mellitus and their offspring. Clin Obstet Gynecol 2007;50(4):972-979.
25. Krosnick A. Economic impact of type II diabetes mellitus. Prim Care 1988;15(2):423-432.
26. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26(3):917-932.
27. Löe H. Periodontal disease: the sixth complication of diabetes mellitus. Diabetes Care 1993;16(1):329-334.
28. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: the San Antonio Heart Study. Diabetes Care 1998;21(7):1167-1172.
29. Lamster IB, Lalla E, Borgnakke WS, Taylor GW. The relationship between oral health and diabetes mellitus. JADA 2008; 139(10 suppl):19S-24S.
30. Del Rosso A, Cerinic MM, De Giorgio F, Minari C, Rotella CM, Seghier G. Rheumatological manifestations in diabetes mellitus. Curr Diabetes Rev 2006;2(4):455-466.
31. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001;17(6):436-443.
32. Vlassara H, Palace MR. Diabetes and advanced glycation end-products. J Intern Med 2002;251(2):87-101.
33. Crispin JC, Alcocer-Varela J. Rheumatologic manifestations of diabetes mellitus. Am J Med 2003;114(9):753-757.
34. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-986.
35. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358(6):580-591.
36. Nathan DM. Finding new treatments for diabetes: how many, how fast . . . how good? N Engl J Med 2007;356(5):437-440.
37. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-1082.
38. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368(9548):1696-1705.
39. Hanefeld M, Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 2008;6(2):153-163.
40. Habener JF. Insulinotropic glucagon-like peptides. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus: A Fundamental and Clinical Text. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000:94-105.
41. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143(8):559-569.
42. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-2635.
43. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-1100.
44. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083-1091.
45. Uwaifo GI, Ratner RE. Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin North Am 2005;34(1):155-197.
46. Meloche RM. Transplantation for the treatment of type 1 diabetes. World J Gastroenterol 2007;13(47):6347-6355.
47. Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 2001;233(4):463-501.
48. Dyck PJ, Davies JL, Clark VM, et al. Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care 2006;29( 101:2282-2288.
49. Merani S, Shapiro AM. Current status of pancreatic islet transplantation. Clin Sci (Lond) 2006;110(6):611-625.
50. Lager I, Attvall S, Blohme G, Smith U. Altered recognition of hypoglycaemic symptoms in type I diabetes during intensified control with continuous subcutaneous insulin infusion. Diabet Med 1986;3(4):322-325.
51. McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 2007;102(6):1343-1357.
52. American Diabetes Association. Diabetes Risk Calculator. "www.diabetes.org/risk-testjep". Accessed July 28, 2008.
53. Kim J, Amar S. Periodontal disease and systemic conditions: a bidirectional relationship. Odontology 2006;94(1):10-21.